Efficacy and safety of direct transition to risperidone long-acting injectable in patients treated with various antipsychotic therapies
| Autor: | Pierre-Michel Llorca, Emilio Sacchetti, Hani-Jürgen Möller, Rossella Medori, Eduard Parellada, Stephen D. Martin |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.drug_class medicine.medical_treatment Global Assessment of Functioning Atypical antipsychotic Injections Intramuscular Patient satisfaction Extrapyramidal symptoms Basal Ganglia Diseases Internal medicine medicine Humans Pharmacology (medical) Antipsychotic Psychiatric Status Rating Scales Risperidone Positive and Negative Syndrome Scale medicine.disease Microspheres Psychiatry and Mental health Psychotic Disorders Schizophrenia Anesthesia Delayed-Action Preparations Quality of Life Female medicine.symptom Psychology medicine.drug Antipsychotic Agents |
| Zdroj: | International clinical psychopharmacology. 20(3) |
| ISSN: | 0268-1315 |
| Popis: | The maintained antipsychotic efficacy of risperidone long-acting injectable (RLAI) was investigated in patients with schizophrenia or other psychoses who were transitioned directly from their previous antipsychotic medication. Patients symptomatically stable, but considered to require a treatment change, received 25 mg of RLAI (increased to 37.5 or 50 mg, if necessary) every 2 weeks for 6 months. Assessments included Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression-Severity (CGI-S), Global Assessment of Functioning (GAF), SF-36 Health-Related Quality of Life Questionnaire and Extrapyramidal Symptoms Rating Scale (ESRS). Of 1876 patients enrolled, 74% completed the 6-month study. The most frequent reasons for treatment change were non-compliance (38%), insufficient efficacy (33%) and side-effects (26%). There was a significant reduction from baseline to endpoint in mean total PANSS score and in the scores on all PANSS subscales and symptom factors (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|